Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

Neurology

Volumn 54, Issue 5, 2000, Pages 1145-1155

  Rice, George P A ^a   Filippi, Massimo ^b   Comi, Giancarlo ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b LHSC UC ^*

Author keywords

Cladribine; MRI; Progressive MS; Suppression of disease activity

Indexed keywords

CLADRIBINE; METHYLPREDNISOLONE; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; ATAXIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INJECTION PAIN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARYNGITIS; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 0034646216     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.5.1145     Document Type: Article

References (38)

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992;31:333-336.
2. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994;36:S6-S11.
3. Goodkin DE. Interferon-β therapy for multiple sclerosis. Lancet 1998;352:1486-1487.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995;1:118-135.
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
6. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997;49:358-363.
7. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
8. Fieschi C, Pozzilli C, Bastianello S, et al. Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations. Mult Scler 1995; 1(suppl 1):S28-S31.
9. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258.
10. Paty DW, Blumhardt LD, on behalf of the transitional PRISMS Study Group. High-dose subcutaneous interferon β-1a is efficacious in transitional multiple sclerosis, a group at high risk for progression in disability. Ann Neurol 1998;44: 503. Abstract W240.
11. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
12. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
13. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
14. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
15. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
16. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.
17. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
18. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology 1995;45:1122-1126.
19. Koudriavtseva T, Thompson AJ, Pozzilli C, et al. Role of a baseline scan in predicting clinical and MRI activity of relapsing-remitting MS patients. J Neuroimmunol 1995; 61(suppl 1):41. Abstract.
20. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995;118: 1601-1612.
21. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44:635-641.
22. Kappos L, Moere EW, Schoetzau A, et al. Predictive value of magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999;353:964-968.
23. Evans AC, Frank JA, Antel J, Miller DH. The role of MRI in clinical trials of multiple sclerosis: comparison of image processing techniques. Ann Neurol 1997;41:125-132.
24. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340:952-956.
25. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13.
26. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996;93:1716-1720.
27. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552-568.
28. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
29. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
30. Barkhof F, Filippi M, van Waesberghe JH, et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 1997;49:1682-1688.
31. Filippi M, Gawne-Cain ML, Gasperini C, et al. Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 1998;50:238-244.
32. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146.
33. Weinshenker BG, Issa M, Baskerville J. Long-term, short-term outcome of multiple sclerosis: a 3-year follow-up study. Arch Neurol 1996;53:353-358.
34. Weinshenker BG, Issa M, Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 1996;46:1613-1619.
35. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113:1477-1489.
36. Sipe JC, Romine JS, Koziol J, Zyroff J, McMillan R, Beutler E. Cladribine improves relapsing-remitting MS: a double blind, placebo controlled study. Neurology 1997;48(suppl 2):A340. Abstract S345.003.
37. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332-339.
38. Beutler E, Piro LD, Savan A. 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma 1991;5:1-8.